Group Discussion

Time: 2:10 pm
day: Post-Conference Workshop Day


• What is the translatability of biomarkers identified in preclinical models into the clinic? How can early trials be used to validate biomarker relevance to disease and treatment?
• What is the role of biomarkers in improving clinical trial design by enriching for patient populations that could benefit from potential treatments?
• What is the role of biomarkers as endpoints in later stage clinical trial (e.g., surrogate efficacy endpoints?) What are the regulatory considerations in using biomarkers as endpoints in clinical trials?
• What role could biomarkers play in terms of commercialization?